Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival AnalysisHajime Uno, L. J. Wei, Brian Claggett et al.|Journal of Clinical Oncology|2014Cited by 777
Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G. Richardson, Irene M. Ghobrial, Eva Medvedova et al.|New England Journal of Medicine|2022Cited by 457
OAB-052: Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trialPrashant Kapoor, Shaji Kumar, Timothy M. Schmidt et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 16